Literature DB >> 18989659

Further characterization of the discriminative stimulus properties of the atypical antipsychotic drug clozapine in C57BL/6 mice: role of 5-HT(2A) serotonergic and alpha (1) adrenergic antagonism.

Scott D Philibin1, D Matthew Walentiny, Sarah A Vunck, Adam J Prus, Herbert Y Meltzer, Joseph H Porter.   

Abstract

RATIONALE: The discriminative stimulus properties of the atypical antipsychotic drug (APD) clozapine (CLZ) have recently been studied in C57BL/6 mice, a common background strain for genetic alterations. However, further evaluation is needed to fully characterize CLZ's discriminative cue in this strain of mice.
OBJECTIVES: The objectives of the study were to confirm the previous findings using a shorter pretreatment time and to further characterize the receptor mechanisms mediating the discriminative stimulus properties of CLZ by testing APDs, selective ligands, and N-desmethylclozapine (CLZ's major metabolite) in C57BL/6 mice.
MATERIALS AND METHODS: C57BL/6 male mice were trained to discriminate 2.5 mg/kg CLZ (s.c.) from vehicle in a two-lever drug discrimination task.
RESULTS: Generalization testing with CLZ yielded an ED(50) = 1.19 mg/kg. Substitution testing with APDs showed that the atypical APDs quetiapine, sertindole, zotepine, iloperidone, and melperone fully substituted for CLZ (> or =80% CLZ-appropriate responding), but aripiprazole did not. The typical APDs chlorpromazine and thioridazine substituted for CLZ (fluphenazine and perphenazine did not). The serotonin (5-HT) (2A) antagonist M100907 and the alpha(1)-adrenoceptor antagonist prazosin fully substituted for CLZ. The H(1) histaminergic antagonist pyrilamine, dopamine agonist amphetamine, and the selective serotonin reuptake inhibitor fluoxetine did not substitute for CLZ. While N-desmethylclozapine did not substitute for CLZ when tested alone, N-desmethylclozapine plus a low dose of CLZ combined in an additive manner produced full substitution.
CONCLUSIONS: CLZ's discriminative cue in C57BL/6 mice is a "compound" cue mediated in part by antagonism of 5-HT(2A) and alpha(1) receptors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18989659     DOI: 10.1007/s00213-008-1385-3

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  61 in total

1.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Authors:  A Schotte; P F Janssen; W Gommeren; W H Luyten; P Van Gompel; A S Lesage; K De Loore; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 2.  Towards a muscarinic hypothesis of schizophrenia.

Authors:  T J Raedler; F P Bymaster; R Tandon; D Copolov; B Dean
Journal:  Mol Psychiatry       Date:  2006-12-05       Impact factor: 15.992

3.  PNU-96415E, a potential antipsychotic agent with clozapine-like pharmacological properties.

Authors:  A H Tang; S R Franklin; C S Himes; M W Smith; R E Tenbrink
Journal:  J Pharmacol Exp Ther       Date:  1997-04       Impact factor: 4.030

4.  Antagonism by neuroleptics of serotonin 5-HT1A and 5-HT2 receptors of normal human brain in vitro.

Authors:  T J Wander; A Nelson; H Okazaki; E Richelson
Journal:  Eur J Pharmacol       Date:  1987-11-10       Impact factor: 4.432

5.  Generalization to atypical antipsychotic drugs depends on training dose in rats trained to discriminate 1.25 mg/kg clozapine versus 5.0 mg/kg clozapine versus vehicle in a three-choice drug discrimination task.

Authors:  A J Prus; S D Philibin; A L Pehrson; J H Porter
Journal:  Behav Pharmacol       Date:  2005-11       Impact factor: 2.293

6.  D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs.

Authors:  B L Roth; S Tandra; L H Burgess; D R Sibley; H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  1995-08       Impact factor: 4.530

7.  Differential effects of fluoxetine and citalopram treatments on serotonin 5-HT(2C) receptor occupancy in rat brain.

Authors:  Esa-Pekka Pälvimäki; Mikko Kuoppamäki; Erkka Syvälahti; Jarmo Hietala
Journal:  Int J Neuropsychopharmacol       Date:  1999-06       Impact factor: 5.176

8.  A comparison of the discriminative stimulus properties of the atypical antipsychotic drug clozapine in DBA/2 and C57BL/6 inbred mice.

Authors:  Joseph H Porter; David Matthew Walentiny; Scott D Philibin; Sarah A Vunck; John C Crabbe
Journal:  Behav Pharmacol       Date:  2008-09       Impact factor: 2.293

Review 9.  Behavioral profiles of inbred strains on novel olfactory, spatial and emotional tests for reference memory in mice.

Authors:  A Holmes; C C Wrenn; A P Harris; K E Thayer; J N Crawley
Journal:  Genes Brain Behav       Date:  2002-01       Impact factor: 3.449

10.  Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase.

Authors:  Liesbeth A Bruins Slot; Luc De Vries; Adrian Newman-Tancredi; Didier Cussac
Journal:  Eur J Pharmacol       Date:  2006-02-21       Impact factor: 4.432

View more
  5 in total

1.  Discriminative stimulus properties of the atypical antipsychotic amisulpride: comparison to its isomers and to other benzamide derivatives, antipsychotic, antidepressant, and antianxiety drugs in C57BL/6 mice.

Authors:  Timothy J Donahue; Todd M Hillhouse; Kevin A Webster; Richard Young; Eliseu O De Oliveira; Joseph H Porter
Journal:  Psychopharmacology (Berl)       Date:  2017-09-18       Impact factor: 4.530

Review 2.  Discriminative stimulus properties of atypical and typical antipsychotic drugs: a review of preclinical studies.

Authors:  Joseph H Porter; Adam J Prus
Journal:  Psychopharmacology (Berl)       Date:  2008-09-16       Impact factor: 4.530

3.  Effects of iloperidone, combined with desipramine, on alcohol drinking in the Syrian golden hamster.

Authors:  Jibran Y Khokhar; Alan I Green
Journal:  Neuropharmacology       Date:  2016-01-12       Impact factor: 5.250

4.  In Vitro and In Vivo Characterization of the Alkaloid Nuciferine.

Authors:  Martilias S Farrell; John D McCorvy; Xi-Ping Huang; Daniel J Urban; Kate L White; Patrick M Giguere; Allison K Doak; Alison I Bernstein; Kristen A Stout; Su Mi Park; Ramona M Rodriguiz; Bradley W Gray; William S Hyatt; Andrew P Norwood; Kevin A Webster; Brenda M Gannon; Gary W Miller; Joseph H Porter; Brian K Shoichet; William E Fantegrossi; William C Wetsel; Bryan L Roth
Journal:  PLoS One       Date:  2016-03-10       Impact factor: 3.240

5.  Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer's disease.

Authors:  Jiansong Fang; Pengyue Zhang; Quan Wang; Chien-Wei Chiang; Yadi Zhou; Yuan Hou; Jielin Xu; Rui Chen; Bin Zhang; Stephen J Lewis; James B Leverenz; Andrew A Pieper; Bingshan Li; Lang Li; Jeffrey Cummings; Feixiong Cheng
Journal:  Alzheimers Res Ther       Date:  2022-01-10       Impact factor: 8.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.